Advanced Biomaterials to Combat Cancer

A special issue of Journal of Functional Biomaterials (ISSN 2079-4983). This special issue belongs to the section "Biomaterials for Cancer Therapies".

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 2750

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Chemistry, Faraday Building, Lancaster University, Lancaster LA1 4YB, UK
2. Materials Science Institute, Faraday Building, Lancaster University, Lancaster LA1 4YB, UK
Interests: polymer synthesis; supramolecular materials; biomaterials; stimuli-responsive materials; drug delivery; tissue engineering; sustainability
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Engineering Department, Lancaster University, Gillow Avenue, Lancaster LA1 4YW, UK
Interests: hydrogels; implant coatings; composites; biopolymers; languages in science
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Science Medical Centre, Saratov State University, Saratov 410012, Russia
Interests: biophysics; drug delivery systems; drugs; theranostics; microcapsules; layer-by-layer assembly; nanoparticles; enzymes; emulsions; mineral particles; magnetic nanoparticles; magneto-mechanical movement; Brillouin spectroscopy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Research Institute of Clinical and Experimental Lymphology, 630060 Novosibirsk, Russia
Interests: cell biology; biochemistry; cancer; bio-nano-materials; platelet-rich plasma; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer causes the death of millions of people worldwide every year (cancer was the second leading cause of death in 2018), necessitating the design and development of new therapeutic strategies, anticancer-drug formulation and advanced personalized methods/materials with which to combat cancer. This Special Issue focuses on advanced biomaterials for combating cancer, including novel biotechnological interventions (e.g., surgical techniques), to use for the effective formulation and delivery of anticancer drugs (which are often challenging to formulate owing to their unique properties under transition from in vitro to in vivo investigation), and to apply for tissue engineering after tumors have been removed (e.g., polymer scaffolds for the regeneration of the affected tissues). This hugely important topic brings together research from many fields of science, and we welcome contributions from the breadth of disciplines involved in addressing it. The scope is not restricted to biomaterials for anticancer applications; contributions on similar topics are also welcome.

Dr. John G. Hardy
Dr. Timothy E.L. Douglas
Dr. Maria Lomova
Dr. Anastasiya Solovieva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • biomaterials
  • drug delivery systems
  • tissue scaffolds
  • regenerative medicine
  • theranostic

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 5598 KiB  
Article
Curcumin-Encapsulated Nanomicelles Improve Cellular Uptake and Cytotoxicity in Cisplatin-Resistant Human Oral Cancer Cells
by Vijay M. Kumbar, Uday Muddapur, Abdullatif Bin Muhsinah, Saad Ali Alshehri, Mohammed Merae Alshahrani, Ibrahim Abdullah Almazni, Manohar S. Kugaji, Kishore Bhat, Malleswara Rao Peram, Mater H. Mahnashi, Sameer J. Nadaf, Sheetalnath B. Rooge, Aejaz Abdullatif Khan and Ibrahim Ahmed Shaikh
J. Funct. Biomater. 2022, 13(4), 158; https://doi.org/10.3390/jfb13040158 - 21 Sep 2022
Cited by 14 | Viewed by 1956
Abstract
Oral cancer has a high mortality rate, which is mostly determined by the stage of the disease at the time of admission. Around half of all patients with oral cancer report with advanced illness. Hitherto, chemotherapy is preferred to treat oral cancer, but [...] Read more.
Oral cancer has a high mortality rate, which is mostly determined by the stage of the disease at the time of admission. Around half of all patients with oral cancer report with advanced illness. Hitherto, chemotherapy is preferred to treat oral cancer, but the emergence of resistance to anti-cancer drugs is likely to occur after a sequence of treatments. Curcumin is renowned for its anticancer potential but its marred water solubility and poor bioavailability limit its use in treating multidrug-resistant cancers. As part of this investigation, we prepared and characterized Curcumin nanomicelles (CUR-NMs) using DSPE-PEG-2000 and evaluated the anticancer properties of cisplatin-resistant cancer cell lines. The prepared CUR-NMs were sphere-shaped and unilamellar in structure, with a size of 32.60 ± 4.2 nm. CUR-NMs exhibited high entrapment efficiency (82.2%), entrapment content (147.96 µg/mL), and a mean zeta potential of −17.5ζ which is considered moderately stable. The cellular uptake and cytotoxicity studies revealed that CUR-NMs had significantly higher cytotoxicity and cellular uptake in cisplatin drug-resistant oral cancer cell lines and parental oral cancer cells compared to plain curcumin (CUR). The DAPI and FACS analysis corroborated a high percentage of apoptotic cells with CUR-NMs (31.14%) compared to neat CUR (19.72%) treatment. Conclusively, CUR-NMs can potentially be used as an alternative carrier system to improve the therapeutic effects of curcumin in the treatment of cisplatin-resistant human oral cancer. Full article
(This article belongs to the Special Issue Advanced Biomaterials to Combat Cancer)
Show Figures

Figure 1

Back to TopTop